Historically, genes targeted by recurrent chromosomal deletions have been identified within the smallest genomic region shared in all patients, the minimally deleted region (MDR). However, deletions this small do not occur in all patients and are a simplification of the impact larger heterogeneous deletions have during carcinogenesis. We use the example of 13q14 deletions in chronic lymphocytic leukemia to show that genes outside MDRs are associated with disease progression. Genomic profiling of 224 patients identified 205 copy number alterations on chromosome 13 in 132 cases. Deletions including DLEU2 were heterogeneous (845 Kb-96.2 Mb) and identified two breakpoint cluster regions within short interspersed nuclear elements proximal to DLEU2 and within long interspersed nuclear elements/L1 repeats distal to GUCY1B2. After defining a deletion class on the basis of size and location, we show that (a) at diagnosis, larger deletions (class II) were associated with a significantly increased risk of disease progression (odds ratio ¼ 12.3; P ¼ 0.005), (b) in progressive patients, class II deletions were enriched (P ¼ 0.02) and (c) this association was independent of IgVH mutational status, ZAP70 expression and ATM/TP53 deletion. Deletion of a 1 Mb gene cluster (48.2-49.2 Mb), including SETDB2, PHF11 and RCBTB1, was significantly associated (Po0.01) with disease progression. Here, we show that the deletion of genes outside MDRs can influence clinical outcome.
Introduction
Chromosomal deletions are recurrent features of human malignancy and can be critical events for the inactivation of tumor suppressor genes in human cells. A plethora of genes have been identified in almost every tumor type through the identification and characterization of minimally deleted regions (MDRs). 1 Although MDRs have been critical 'signposts' to the location of cancer genes, they are a simplification of the architecture and gene content of these deletions in patients. Indeed, deletions are invariably larger, and multiple nonoverlapping MDRs are often described.
One such example is deletion of the long arm of chromosome 13, which is the most frequent alteration in chronic lymphocytic leukemia (CLL). Early G-banding demonstrated that 13q deletions involved multiple non-overlapping chromosomal regions. 2 Although it was initially suggested that RB1 was the pathogenic locus, 3 homozygous deletions at a more telomeric locus were identified. [3] [4] [5] Physical maps of this region also identified several non-overlapping MDRs, [6] [7] [8] implicating a multigenic tumor suppressor mechanism. Ultimately, a 10 kb transcript-rich MDR including exons of two genes, DLEU1 and DLEU2, was identified. 9 Sequence mutations and aberrant methylation patterns in this region have not been observed. [10] [11] [12] The identification of the miR15a/16-1 microRNA cluster within this region was a pivotal observation, 13 and it is now clear that this cluster drives a lymphoproliferative phenotype in vivo.
14 Interestingly, only a fraction of miR15a/16-1 knock-out mice developed B-cell malignancies, whereas the MDR-deleted mice exhibited more aggressive disease. This observation supports a multigenic hypothesis, and TRIM13 (DLEU5) and DLEU7 have been implicated, possibly through altered ubiquitination or NF-KB signaling. 15, 16 It has been proposed that 13q deletions could be categorized into two types; Type I deletions target a region including the MDR, whereas larger Type II deletions include the RB1 locus and were enriched in treated patients and those with higher Rai stage. 17 The significance of large 13q deletions and RB1 in particular, is further emphasized by their association with elevated genome complexity. 18 It is likely that the biological consequence of a unique deletion anatomy is complex, resulting in the disruption of multiple regulatory sequences. Furthermore, this is likely to be the situation with 13q deletions in other tumor types, such as lymphoma, multiple myeloma and prostate cancer, as well as deletion events in cancer in general. Here, we employ genomic profiling to show that 13q deletion size is associated with disease progression. As a consequence, we propose a novel gene cluster centromeric to the 13q MDR that may contribute to clinical outcome.
Materials and methods

Patients and molecular diagnostic assays
A total of 224 CLL patients diagnosed on the basis of standard morphologic and immunophenotypic criteria were included in this study and sub-divided into three cohorts (Supplementary Table 1 ). Cohort I comprised 63 patients, where samples were taken at disease presentation from patients with either stable disease for at least 5 years (n ¼ 38) or progressive disease within 3 years (n ¼ 25). Cohort II consisted of 64 unselected patient samples taken at disease progression ranging from 0 to 22.5 years after diagnosis (median 2.3 years). Cohort III consisted of samples taken at enrollment to the UK CLL4 treatment trial 19 from 97 patients treated on the fludarabine and cyclophosphamide arm, sub-divided on the basis of treatment response; with either complete (n ¼ 49), partial (n ¼ 40) or no response (n ¼ 8) to treatment. Informed consent was obtained from all patients in accordance with the Helsinki declaration.
Fluorescence in situ hybridization analysis was performed on all cases for the presence of established rearrangements using a range of commercially available probes (Abbott Diagnostics, Maidenhead, UK; DakoCytomation, Glostrup, Denmark) according to the manufacturers' instructions. Chromosomal analysis was performed and described according to the International System for Human Cytogenetic Nomenclature.
20 ZAP70 and CD38 expression was determined as previously described, 21, 22 where 10 and 30% positive cells were classed as positive, respectively. IGHV genes were sequenced as previously described 23 and a cut-off of X98% germ-line homology was taken to define the unmutated sub-set (Supplementary Materials  & Methods and Supplementary Table 1) .
Genomic profiling DNA extraction, SNP6.0. array hybridization and data extraction. Genomic DNA was extracted from fluorescentactivated cell sorter-purified CD19 þ lymphocytes, CD19
À granulocytes and buccal swabs using standard approaches, and the concentration and purity was assessed using gel electrophoresis and spectrophotometry (NanoDrop ND-1000, Thermo Scientific, Wilmington, NC, USA). DNA was amplified, labeled and hybridized to the Affymetrix SNP6.0 platform according to the Affymetrix Cytogenetics Copy Number protocol (Affymetrix, Santa Clara, CA, USA) (Supplementary Materials & Methods). Each array was scanned (GeneChip Scanner 3000 7G, Affymetrix) and processed using proprietary software (GeneChip Operating System software, Affymetrix). The feature-extracted .CEL file was then quality controlled using the Genotyping Console 2.1 software (Affymetrix), and only those achieving manufacturers' quality cut-off scores were included in this study.
SNP6.0.FData analysis
The .CEL files were imported into Partek Genomics Suite (Partek Inc., MO, USA) for copy number and loss-of-heterozygosity analysis. Initially, a paired and unpaired analysis of 32 samples with matched germline DNA was performed. Employing the 270 HapMap Reference baseline (Affymetrix) as a control and excluding germline copy number variants based on published data (Database of Genomic Variants, http://projects.tcag.ca/ variation/), a concordance of 497% was observed and there was no difference in how individual cases were defined on the basis of genome complexity. As a consequence, the entire cohort was analyzed using the unpaired approach. The raw fluorescence intensity values for each array feature were extracted from the .CEL image file, normalized and aligned onto the human genome sequence (Build 36.3). Copy number gains and losses were defined as a deviation of probes from normal value of 2, within a consecutive genomic window of 50 Kb. Copy number changes were verified by two independent researchers. The allele ratio was calculated for each sample using the HapMap Allele Reference baseline (Affymetrix), and in the absence of paired normal DNA, copy number neutral loss-of-heterozygosity (CNNLOH) was as a region greater than 20 Mb, extending to a telomere.
Confirmation with array-based comparative genomic hybridization
To confirm the SNP6.0. data, DNA samples from 22 patients were also profiled using the Human Genome CGH Custom Microarray (8 Â 60K, Agilent Technologies, Stockport, UK) according the manufacturer's instructions. Test DNA samples were sex-matched with normal genomic reference DNA (Promega, Southampton, UK) and analysis was performed using proprietary software (DNA Analytics, Agilent Technologies).
Statistical analysis
Statistical analysis was performed using STATA (9.2) on a linux platform. Logistic regression was employed within the individual cohorts for binary response variables. Variables examined included the disease progression variable (stable or progressive disease), presence/absence of 13q deletion and class I/II 13q deletion category. Age at diagnosis and gender were included as covariates in all models where available (age at diagnosis was not available for cohort III). In cohorts I and II, overall survival was defined as time, in months, from diagnosis to death or to the last follow-up date for survivors. In cohort III, overall survival was defined as time from randomization, on entry, to the CLL4 clinical trial, to death, or to the follow-up date for survivors. Progression-free survival was only measured in cohort III and was defined as time from randomization to relapse needing further therapy, progression or death or to the follow-up date for those with no progression/death. In all cohorts, time to first treatment was defined as time from diagnosis to therapy, or to the last follow-up date for untreated patients. Before survival analysis, power calculations were performed and showed that our total cohort was powered (0.8) to detect a hazard ratio of 2.0 at the 5% level, based on the median overall survival of our 13q-deleted patients. 24 Cox regression was undertaken for survival analyses examining the impacts of 13q deletions on overall survival and time to first treatment on the whole sample stratified by cohort and on progression-free survival for cohort III. Fixed covariates included in the models were IgVH mutation status and 17p deletion along with genetic complexity.
Results
CLL patients are characterized by considerable genomic heterogeneity
Analysis with the SNP 6.0 platform identified 776 acquired copy number alterations (CNAs) in 224 patients (mean 3.5, range 0-45), including 24 CNNLOH events and 33 whole chromosome gains and losses (trisomy 12, n ¼ 24) (Supplementary Table 2 ). Of the remaining CNAs, deletions were more frequent than gains (n ¼ 593 vs n ¼ 126). Sub-chromosomal CNAs size ranged from 52 kb to 131 Mb. Deletions of ATM and TP53 were observed in 25% (n ¼ 56) and 9% (n ¼ 19) of cases, respectively. Apparently normal and complex genomes were observed in 18 and 96 patients, respectively, where complexity was defined as previously reported (X3 CNAs excluding aneuploidy). 18 Microarray data was concordant with diagnostic fluorescence in situ hybridization for 96.2% of the tests performed (790/816). Array-CGH analysis confirmed the position of all the CNAs identified in 22 patients by SNP6.0 analysis. We visually inspected the copy number data and dichotomised deletions into two classes on the basis of size and inclusion of the MDR; both deletion classes included the MDR, whereas class I (o2 Mb in size, n ¼ 63) and II (42 Mb in size, n ¼ 68) deletions were less than or greater than the 50th percentile of deletion size, respectively (Supplementary Table 4 ).
In spite of the breakpoint heterogeneity, a 210 kb proximal breakpoint cluster region (BCR) was identified in 31 patients, located between 49.3 and 49.5 Mb, targeting C13orf1, TRIM13, KCNRG and exons 7-11 of the DLEU2 gene. A 210 kb distal BCR was identified in 46 patients, located between 50.35 and 50.56 Mb, targeting RNASEH2B and GUCY1B2 (Figures 1c  and d) . Interestingly, class I deletion breakpoints were often within the proximal BCR and distal BCR. Next we analyzed both BCRs for the presence of repetitive DNA elements that may provide insight into how these CNA arose. In total, 98 of 181 breakpoints within these regions were within repeat regions. The most frequently targeted DNA repeats were short-and long interspersed nuclear elements in the proximal and distal BCR, respectively (Supplementary Figure 4) . Deletion breakpoints were frequently intragenic, accounting for 219 breakpoints within 64 genes including RB1, FNDC3A, KPNA3, DLEU7 and INTS6 (Supplementary Figure 5) .
Multiple deletions can target 13q but are not associated with genome complexity to be confined to chromosome 13. With the exception of a single case (#258) involving loss of TP53, all these cases exhibited one or two CNAs on other chromosomes. Recently, it has been suggested that 13q deletion size is an independent predictor of genomic complexity. 18 To investigate this association further, we used our 13q deletion classification, and although there was an association between a class II 13q deletion and increased genetic complexity in cohort I, this was confounded by the high frequency of mono-and biallelic deletion of 13q (Supplementary Table 5 ). This, with the observation that in cohorts II and III, a class II deletion was not associated with a complex genome, suggests a more subtle relationship between 13q deletion size and genome complexity through disease evolution.
In early stage CLL 13q deletion size is associated with disease progression
In-line with previous genetic studies of CLL the presence of a 13q deletion at disease presentation (cohort I) was found to be more associated with stable disease (odds ratio ¼ 0.16, 95% confidence intervals: 0.04-0.60; P ¼ 0.007). However, 13q deletion size in cases that went on to progress, defined as requiring treatment within 3 years, were significantly larger when compared with cases with stable disease after 5 years (P ¼ 0.04; median size 3.5 vs. 1.2 Mb, Table 1a ).
In cohort I, 31 stable cases (82%) had 13q deletions, of which, seven (23%) were class II. In comparison, only 13 progressive cases (52%) had a deletion and 9 (69%) were class II. After controlling for age at diagnosis and gender, class II deletions were found to be associated with an increased risk of disease progression (odds ratio ¼ 12.3; 95% confidence intervals: 2.1-72.2; P ¼ 0.005) compared with cases with class I deletions. On the basis of this initial finding we went on to investigate whether class II deletions were enriched in two further CLL cohorts sampled subsequent to progression. Class II deletions were found to be enriched in cohorts II and III when compared with cohort I (60 vs. 36%; P ¼ 0.02), supporting a role for 13q deletion size in progressive disease and also implicating genes outside of the MDR on 13q as clinically and biologically relevant (Figures 2a and c and Table 1b) .
Type II 13q deletions are defined by deletion of RB1, as described by Ouilette et al. 17 and have previously been found to be enriched in patients who received treatment or had a higher clinical stage. 17 Therefore, 13q deletion types were assigned to our cases. By logistic regression, 13q deletion type II was shown to be associated with disease progression in cohort I (odds ratio ¼ 6.7; 95% confidence intervals: 1.22-37.25; P ¼ 0.03 Table 1a ). However, this association was not stronger than the risk of disease progression associated with gender (P ¼ 0.03), and was far less predictive of progression than the class II cut-off, strongly supporting the latter as a predictor of disease progression.
13q deletion size may provide additional clinical information alongside established prognostic markers
In light of our findings that a class II 13q deletion predicts progression, we examined whether this is independent of established prognostic markers. Cohort I cases that progressed were more likely to be ZAP70 positive (P ¼ 0.03) and have an unmutated IgVH gene (P ¼ 0.001). When cohort I cases were stratified by the presence of a class II deletion, the association with disease progression was independent from all prognostic markers tested for, except for CD38 positivity (P ¼ 0.03, Table 2 ). Cohorts II and/or III supported the cohort I finding as the presence of a class II deletion was not associated with CD38, ZAP70 positivity, 17p or 11q deletion by fluorescence in situ hybridization, IgVH mutation status, white blood cell count, beta-2-microglobulin levels and lactose dehydrogenase activity (Table 2) . It has previously been demonstrated that CLL cells exhibiting high clonal populations of 13q-deleted cells (480%) have inferior survival. Moreover, the presence of a biallelic 13q deletion has been associated with a poor outcome in certain studies. Neither of these observations predicted deletion class in our patients (Supplementary Table 6 ).
Multivariate Cox proportional hazard model analysis, stratified by cohorts I, II and III, did identify associations between 17p Table 6 ). Furthermore, the presence of either a biallelic 13q deletion or a deletion of RB1 (Type II deletion) was not associated with an adverse outcome. In cohort III, we determined whether deletion size predicted response to treatment (fludarabine and cyclophosphamide). Deletions were larger (mean size (partial response/no response) 7.62 versus (complete response) 5.65 Mb) and class II deletions were more frequent in patients with partial or no response to treatment. However, the difference in deletion size was not statistically significant (P ¼ 0.343).
Deletion of a gene cluster centromeric to the 13q MDR is more frequent in progressive patients
As large 13q deletions at presentation were found to be associated with disease progression, deletions were mapped onto 13q gene architecture to determine whether there is a commonly deleted gene cluster associated with disease progression. In cohort I, a detailed analysis of the genes contained within these deletions, revealed a group of 15 genes outside the MDR region that were more frequently deleted in cases with subsequent progressive disease when compared with the deleted genes in cases with stable disease (Po0.01; Figures 2d and f and Table 3 ). In all, 14 of these genes were in a 1 Mb gene cluster located between the MDR and RB1 (RB1 deletions occurred in 54 individuals), suggesting that these genes may be associated with clinical outcome. Deletion of the same set of genes was observed in progressive cohorts II and III. Interestingly, this association was further supported by profiling the second deletion event in cases with biallelic loss. Class II deletions of the second allele were exclusively observed in progressive cases, and showed enrichment of the same 1 Mb cluster of deleted gene (Supplementary Figure 1C and D) . This shows that these genes can be completely inactivated by biallelic loss, supporting a tumor suppressor role.
Discussion
Here, we show the development of a novel approach for the identification of putative cancer genes outside established MDRs, using enrichment analysis based on clinical outcome Although the MDR (142.9 Kb) we identified is larger than those previously published, 9,13 it more accurately reflects the in vivo situation. 17, 25 It may also explain the incomplete penetrance of a leukemia phenotype observed in the 13q MDR/miR15a/16-1 mouse model. 14 The demonstration that the DLEU2 promoter can control miR15a/16-1 expression is a likely explanation for the two cases we found with deletion of the DLEU2 promoter region but not the miR15a/16-1 cluster. 26 We refine two BCRs, proximal and distal, to the MDR that may be prone to breakage and recombination in CLL B cells. In light of the BCRs identified here, it is clear that 13q deletions can be grouped thus: class I deletions are confined to a 2 Mb region where breakpoints often occur in the two BCRs identified, which in addition to the genes within the MDR, include FLJ31945, FAM10A4, BCMS and DLEU7; class II deletions extended beyond this region in either a centromeric and/or telomeric direction, encompassing a large number of additional genes. Rather than being the result of consistent BCRs, class II deletions displayed highly heterogeneous breakpoints suggesting that these classes of deletion may be mechanistically dissimilar. However, rare BCRs may emerge from a larger study.
At diagnosis (cohort I), we show that 13q deletions are significantly larger in patients who subsequently developed progressive disease. Indeed, class II deletions predict disease progression more strongly than previous definitions, 17 implicating genes positioned between the MDR and RB1. The clinical importance of deletion size is further supported by, (a) their enrichment in samples taken subsequent to disease progression (Cohort II and III) and (b) their independence of established prognostic markers, such as TP53/ATM deletions and IgVH mutational status. Contrary to the previous suggestion that deletion of DLEU7 may be associated with adverse outcome, we have shown that class I deletions, which contain DLEU7, are not associated with a poor prognosis. 16 Although the stratification of our patients into three distinct cohorts is necessary to account for sources of biological heterogeneity, this reduces statistical power relative to an equivalently sized single-cohort study. Although, our data demonstrates the clinical importance of 13q deletion size, it was not possible to confirm this with measures of event-free survival, suggesting either a lack of power because of a minor impact on prognosis (HRo2.0) or a more complex relationship between 13q deletion heterogeneity and clinical outcome. We identified deleted 13q genes that are strongly associated with disease progression at diagnosis (cohort I) and confirmed enrichment of these gene deletions in progressive patients (cohorts II and III). In addition to supporting the proposed role of RB1 in these deletions, 17 our approach also identifies a cluster of genes positioned between the MDR and RB1. SETDB2 is a methyltransferase with a role in chromosome condensation and segregation. 27 Given its capacity for lysine methylation, it is also possible that SETDB2 may be involved in post-translation control of P53 through methylation of lysine 372. 28 In light of the prognostic impact of P53 deregulation, this is an interesting avenue for further study. The deletion of other genes, such as PHF11, which is expressed in B-and T cells, and controls gene expression through interactions with the p65 subunit of NF-kB, 29 and RCBTB1, which has been implicated in ubiquitination through its role as a substrate for a CUL3 E3 ligase, 30 may also be important genes within the region. Interestingly, the result of a unique 13q deletion may be the loss of multiple genes that contribute to the disruption of a small number of key biological pathways, causing a variable degree of pathway dysfunction and a heterogeneous impact on prognosis. We confirm the presence of CNNLOH targeting chromosome 13, resulting exclusively in the duplication of a deletion targeting the MDR. Although this suggests that the consequence of the CNNLOH event is loss of both copies of genes within the MDR, it resulted in homozygosity of the cluster of genes shown to be associated with progressive disease. These CNNLOH events were detected in patients who progressed and are likely to be valuable for the identification of sequence changes or epigenetic alterations within this region.
Our data shows that 13q deletions can be the result of a complex series of CNAs, which in three patients include focal deletions targeting RB1 in addition to a loss of the MDR, suggesting the RB1 may contribute to instability of chromosome 13 . It has been suggested that there may be gene(s) on 13q that are contributing to complexity in certain CLL patients, as an association between Type II deletions and genome complexity has already been demonstrated. 18 However, our study included more 13q-deleted patients with complex genomes, and suggests that the association is more subtle. Class II deletions were only associated with a complex genome at disease presentation and our data suggests that this relationship is confounded by the high frequency of mono-and biallelic 13q deletions. The relationship between 13q and genome complexity might be complicated by multiple mechanisms contributing to genome instability later in disease that are not present at earlier stages. Also, it may identify weaknesses in interpreting data derived from large heterogeneous cohorts of CLL patients that include samples taken at different stages of disease evolution and from treated/ untreated patients. Our findings suggest that care is required when interpreting this type of data, and in fact a more accurate insight into associations between CNA and disease characteristics can be obtained from smaller homogeneous subgroups. Although our analysis demonstrates that complexity can be accurately assessed using unpaired analysis, it is possible that any association with this measure may be confounded by the absence of analyzing germ line material.
Here, we show that the consequence of 13q deletions in CLL is the loss of a variable number of gene loci. Although it has been proposed that chromosomal deletions, including those targeting 13q14 in CLL, may drive disease pathogenesis through targeting multiple genes, this study provides the first clinical associations to support this hypothesis. Although this observation requires further validation, additional prognostic information could be provided in the clinical setting using fluorescence in situ hybridization, multiplex ligation-dependent probe amplification and array-based comparative genomic hybridization to distinguish between informative deletion sizes. These deletions have the potential to deregulate multiple genes in a number of key biological pathways that include key regulators of cell cycle control, ubiquitination and NF-kB signaling. This observation has application to cancer in general, where recurrent CNAs are equally heterogeneous. Although the historical analysis of MDRs has identified genes involved in carcinogenesis, genes outside MDRs that contribute to a more aggressive disease will not be identified. Moreover, it is plausible that the MDRs without an identified pathogenic mechanism are the result of inherent instability within these genomic regions. It is deletion of genes outside the MDR that may provide the cancer cell with a growth advantage. The application of high-throughput next generation sequencing technologies to these large deleted regions will confirm these hypotheses and will identify a further sub-set of relevant genes that may provide valuable prognostic information. These deletion events and the consequential loss of a variable number of gene loci may represent a paradigm for individualized medicine, where deletion size and location reflects the degree that certain biochemical pathways have been compromised, which in turn may impact on treatment response. In conclusion, we provide the first evidence that deletion size can influence progression, providing verification that deletions can target multiple, clinically relevant loci. From the expansion of this approach into other tumor types, a large number of novel genes will surely emerge, expanding our understanding of carcinogenesis and ultimately leading to improved management of patients with cancer.
Conflict of interest
The authors declare no conflict of interest.
